{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q38424",
      "entity_text" : "ALT",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:10407" ],
      "TissueType" : [ "tissuelist:TS-0564" ],
      "Organ" : [ "uberon:UBERON:0000479" ]
    }
  },
  "verbose_text" : "Eligibility for the treatment of chronic hepatitis B. To assess treatment eligibility both in HBeAg positive and HBeAg negative patients, HBsAg must be consistently detectable for at least six months, and at least two out of the three criteria below (evaluated concurrently) must be met : HBV-DNA> 2,000 IU/ml; ALT level exceeding the upper limit of normal; signs of liver inflammation or fibrosis.",
  "reading_complete" : "2020-08-03T18:26:01Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T18:20:40Z",
  "trigger" : "level",
  "evidence" : [ "ALT level" ],
  "pmc_id" : "5497479",
  "score" : 0
}